Skip to main content
. Author manuscript; available in PMC: 2023 May 4.
Published in final edited form as: Cancer Immunol Res. 2023 May 3;11(5):629–645. doi: 10.1158/2326-6066.CIR-22-0655

Figure 4. Changes in PMN-MDSCs and BMDMs parallels checkpoint blockade efficiency.

Figure 4.

A) Flow cytometry of the indicated immune cells in GBMs, TDLNs and spleens of mice treated as indicated. EGFR-WT n=10, 7, 6, 8 and EGFRvIII n=9, 4, 4, 5 for IgG, PD-1, CTLA4 and PD-1/CTLA4 checkpoint blockade respectively and n=6 for recurrent EGFR-WT. B-D) Flow cytometry of PMN-MDSCs and BMDMs from GBM and spleen of mice treated as indicated. E) Ratio of CD8:PMN-MDSCs from GBMs treated as indicated. F,G) Flow cytometry of relative CD8+ and CD4+ TEM and TCM cell subset from GBM (F) and TDLNs (G) tissues of mice treated as indicated. Non-bracketed comparisons to IgG controls (B-G). Mean±SEM of biological replicates. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, unpaired t test, two-tailed.